M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds

M Cecilia Martins-Costa¹²³, Lucas L Cunha¹, Susan C Lindsey¹, Cleber P Camacho¹, Renata P Dotto¹, Gilberto K Furuzawa¹, M Sharmila A Sousa¹, Teresa S Kasamatsu¹, Ilda S Kunii¹, Márcio M Martins¹, Alberto L Machado¹⁴, João R M Martins¹, Magnus R Dias-da-Silva¹ and Rui M B Maciel¹⁴

¹Department of Medicine, Thyroid Diseases Center and Laboratory of Molecular and Translational Endocrinology, Division of Endocrinology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
²Center for Endocrinology and Metabolology, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil
³Department of Medicine, Universidade de Fortaleza, Fortaleza, CE, Brazil
⁴Fleury Medicine and Health, São Paulo, SP, Brazil

Abstract

Germline mutations in codon 918 of exon 16 of the RET gene (M918T) are classically associated with multiple endocrine neoplasia type 2B (MEN 2B) with highly aggressive medullary thyroid cancer (MTC), pheochromocytoma and a unique phenotype. The objectives of this study are to describe the rare M918V RET mutation discovered in 8 MTC kindreds from Brazil lacking the MEN 2B phenotype classically observed in M918T patients and to investigate the presence of a founder effect for this germline mutation. Eight apparently sporadic MTC cases were diagnosed with the germline M918V RET mutation. Subsequently, their relatives underwent clinical and genetic assessment (n = 113), and M918V was found in 42 of them. Until today, 20/50 M918V carriers underwent thyroidectomy and all presented MTC/C-cell hyperplasia; the remainder carriers are on clinical follow-up. None of the M918V carriers presented clinical features of MEN 2B. Their clinical presentation was heterogeneous, and the age at tumor diagnosis ranged from 24 to 59 years. Lymph node metastases were present in 12/20 patients, and presumable distant metastases in 2/20; in contrast, we observed a carrier of up to 87 years of age without evidence of MTC. Ethnographic fieldwork and haplotype analyses suggested that the founder mutation first settled in that area fifteen generations ago and originated from Portugal. Our study is the first to demonstrate the RET M918V mutation co-segregating in 8 familial MTC kindreds with validated evidence of a founder effect. We suggest that M918V MTC should be clinically considered an American Thyroid Association (ATA) moderate-risk category.

Introduction

Activating RET oncogene germline mutations causes multiple endocrine neoplasia type 2A (MEN 2A) and type 2B (MEN 2B). Virtually, all patients with a RET mutation will develop medullary thyroid cancer (MTC).

In the absence of associated pheochromocytoma (PHEO) and primary hyperparathyroidism (HPTH), MEN 2A is subclassified as familial medullary thyroid carcinoma (FMTC) (Wells et al. 2015).
The understanding of the genotype/phenotype correlation of RET mutations has increased over recent decades due to the widespread practice of RET sequencing and careful long-term clinical follow-up of affected kindreds (Signorini et al. 2014, Wells et al. 2015). This knowledge has allowed recommendations on the timing of prophylactic thyroidectomy and surgery extent based on stratified mutation risk levels (Brandi et al. 2001, Kloos et al. 2009, Wells et al. 2015). In fact, increased genetic screening for RET mutations, particularly for apparently sporadic MTC, has also led to the possibility of discovering new mutations of which the transforming activity remains uncertain (Chen et al. 2010).

Germline mutations in codon 918 in exon 16 of the RET gene (M918T) are characteristically associated with multiple endocrine neoplasia type 2B (MEN 2B) with highly aggressive MTC, PHEO and a unique phenotype (Carlson et al. 1994, Hofstra et al. 1994, Eng et al. 1994, Wells et al. 2013, 2015, Frank-Raue & Raue 2015). To date, the M918V mutation was described in only one patient with MTC in a large Italian cohort and in one family member who had not developed MTC at the time of publication (Coscì et al. 2011).

Here, we describe this rare methionine-to-valine substitution in the 918 codon of the RET gene in eight MTC kindreds without the MEN2B phenotype classically observed in M918T patients. Moreover, we report the clinical, molecular and histological features of such families and the presence of a founder effect for this germline mutation.

Patients and methods

Index patients, their relatives and controls

As part of the Brazilian Research Consortium for Multiple Endocrine Neoplasia (BRASMN), we evaluated 60 index cases of MTC (31 sporadic, 28 MEN 2A and 1 MEN 2B) in Ceará, a Northeastern State of Brazil. Eight apparently sporadic MTC patients were identified with the M918V RET mutation. Then, we have invited the relatives at-risk to enter in this study and, at the time of this report, 113 (female n=84; male n=29) members were assessed.

Additionally, 40 thyroid-healthy individuals originating from the same state but unrelated to the patients were investigated as a control group.

The study protocol was approved by the internal review board of the Universidade Federal de São Paulo (CAAE: 16441414.9.1001.5505111), and all patients received genetic counseling before and after RET testing.

Clinical evaluation and follow-up of M918V carriers

Clinical evaluation consisted of medical history and physical examination. We particularly looked for syndromic features and the MEN 2B phenotype, including PHEO, marfanoid habitus, mucosal neuromas and ganglioneuromatosis (Camacho et al. 2008).

We performed peripheral blood collection to assess calcitonin, carcinoembryonic antigen (CEA), thyroid-stimulating hormone (TSH), free thyroxine (FT4), parathyroid hormone (PTH) and total calcium measurements. For those who presented PTH levels above the upper limit of the range, we measured 25-hydroxyvitamin D. We also measured plasma metanephrines, as well as 24-h urinary catecholamines and metanephrines for biochemical investigation of PHEO.

Cervical and abdominal ultrasound (US) was performed with a LOGIQ scanner (GE Healthcare Bio-Science) using a 12-MHz transducer integrated with color-Doppler examination. Thyroid nodules with suspicious features for malignancy were submitted to US-guided fine needle aspiration biopsy (FNAB) using a 23-gauge needle (25 × 0.6 mm) attached to a 10-mL syringe.

For patients with an MTC diagnosis, the clinical management, including imaging investigation, was performed in accordance with American Thyroid Association (ATA) guidelines (Kloos et al. 2009, Wells et al. 2015). However, because the M918V mutation has not yet been classified in any MTC guideline, we clinically approached the carriers based on serum calcitonin and CEA measurements, as well as the FNAB results of detected thyroid nodules; only those patients with positive results for these tests were referred for surgery. After histological confirmation of MTC, and classification of the neoplasia according to the TNM (tumor, node, metastasis) staging system (American Journal Committee on Cancer 2010), those patients were followed in accordance with the ATA guidelines (Wells et al. 2015). The remaining carriers who present normal calcitonin and cervical ultrasound examination were maintained on a careful follow-up.

Laboratory studies

Basal plasma calcitonin was measured using an in-house immunofluorometric assay, with cut-off values of 18.4 pg/mL for males and 7.8 pg/mL for females (Camacho et al. 2014). CEA, TSH and FT4 were measured by electrochemiluminescent immunoassays (Elecsys analyzer, Roche Diagnostics GmbH). The normal ranges...
were as follows: CEA, smokers: <5ng/mL, non-smokers: <3ng/mL; TSH, 0.27–4.2mIU/L; FT4, 0.93–1.7ng/dl; and PTH, 15–65ng/mL. Total calcium was measured using a colorimetric assay (Olympus AU400 analyzer, Beckman Coulter Biomedical K.K., Shizuoka, Japan). The normal ranges were 8.8–10.6 ng/mL for adults and 8.5–11 ng/mL for children. The 25-hydroxyvitamin D levels were measured using an immunoenzymatic assay. The normal range was 30–60 ng/mL (Maeda et al. 2014). Plasma metanephrines were measured using liquid chromatography–tandem mass spectrometry (XEVO TQ-S, Milford, MA, USA), and the normal range was <0.5 nmol/L for metanephrine and <0.9 nmol/L for normetanephrine. Urinary catecholamines and metanephrines were measured using high-performance liquid chromatography (Chromsystems Instruments & Chemicals GmH, Munich, Germany). The normal ranges for catecholamines were as follows: up to 97 µg/24h for norepinephrine, up to 500 µg/24h for dopamine and up to 27 µg/24h for epinephrine. The normal ranges for metanephrines were as follows: up to 320 µg/24h for metanephrine and up to 390 µg/24h for normetanephrine.

Genomic DNA was extracted from peripheral blood leukocytes using an in-house protocol (Kizys et al. 2012). Sequence analysis of hot-spot bearing exons 8, 10, 11 and 13–16 was performed; in addition, extended RET gene analysis was performed in all M918V carriers who had histopathological confirmation of MTC/CCH to exclude mutations in other exons (Lindsey et al. 2012). Briefly, each exon was sequenced at least twice and in both directions. The cycling conditions were as follows: 5 min at 94°C, followed by 38 cycles of 20 s each at 94°C and 30 s at 60°C and an extension step of 2 min at 72°C. PCR products were direct-sequenced using an ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). The sequences were analyzed using the BioEdit Sequence Alignment Editor and CLC Main Workbench 6 (http://www.clcbio.com) and compared with reference data available in the NCBI GenBank (RefSeq NG_007489) and the Ensembl Genome Browser (Lindsey et al. 2012).

**Genealogical fieldwork**

The observation that the highest concentration of patients with the M918V RET mutation occurred in the same region in the northeast area of the State of Ceará in association with the anecdotal perception of high consanguinity among inhabitants led us to perform a genealogical investigation of the families, including data collection from these families in the local church and municipality archives, such as birth, marriage and death registries.

**Founder effect and mutation age estimation analysis**

We hypothesized that a founder effect would explain the high frequency of the M918V RET mutation in those patients from northeastern Ceará. Haplotype analysis of four RET-flanking microsatellite markers, D10S197, D10S196, D10S1652 and D10S537, was performed to track the founder effect (Qi et al. 2011). The first marker was placed at position 50.04cM, and the other three markers were at positions 70.07, 80.61 and 89.16cM. The chromosome map distances were derived from the deCODE map (https://www.ncbi.nlm.nih.gov/probe/).

GenePop was used to perform the Hardy-Weinberg exact test (Rousset 2008). Haplotypes of the patients and controls were reconstructed using the statistical software package PHASE, version 2.1 (Stephens et al. 2001, Stephens & Donnelly 2003, Stephens & Scheet 2005). We constructed the phylogenetic tree of the studied families with POPTREE2 software by estimating the genetic distance measures (Takezaki et al. 2010).

The proportion of haplotypes commonly observed in all carriers was reduced with time. This allowed us to estimate the age of the founder mutation. Disease mapping using Linkage disEquilibrium (DMLE) version 2.3 (Reeve & Rannala 2002) estimated the age of M918V RET mutation based on the disease chromosomes sampled and the population growth rate. Because the M918V RET mutation was recently described (Cosci et al. 2011), the proportion of chromosomes sampled was difficult to calculate. Therefore, three different analyses were performed using a different calculation for the proportion of mutation-carrying chromosomes sampled: 0.015, 0.01 and 0.005 (Caleca et al. 2014). The population growth rate was estimated as described previously (Papi et al. 2009).

**Statistical analysis**

The primary data are presented as the mean ± standard deviation (s.d.), median and minimal and maximal values. SPSS software (version 23; SPSS) was used to perform the analysis. A P value <0.05 was considered significant.
Results

Clinical and genetic diagnosis of FMTC in eight kindreds carrying the RET M918V mutation

After the detection of the germline M918V RET mutation in 8 apparently unrelated MTC indexes cases, we extended the analysis to their relatives (Fig. 1). Consequently, we have studied 121 individuals (83 women and 38 men), being 8 index cases and 113 at-risk relatives. From these 113 at-risk relatives screened, 42 were diagnosed with this mutation and 71 were non-carriers. In 2 families (F3 and F6), the mutation was identified in 2 generations. In 3 families (F1, F4 and F5), the mutation was identified in 3 generations. For 3 index cases (F2, F7 and F8), only one individual is noticeably affected because the other family members have not answered our call for the clinical and genetic evaluation to date (Fig. 1).

At the moment of RET screening, 4 of these 42 M918V-positive relatives had already been submitted to total thyroidectomy, although they were not aware that their thyroid disease had a hereditary component and that it was related to a common bond with index patients (patients F1.6, F1.7, F1.8 and F1.9). The remainder 38 relatives positive for M918V had not performed any surgical procedure at the time of RET screening.

The clinical and biochemical features of all M918V carriers are shown in Table 1. At the initial assessment after RET screening, 42% (14/33) of the patients presented serum calcitonin levels above the limit of reference; 20% (6/30) had elevated CEA. Two of 25 patients presented elevations of PTH, both related to decreased levels of vitamin D (18 and 21 ng/mL). None of the M918V carriers presented hypercalcemia or elevation of plasma and 24-h urinary metanephrines.

Therefore, from the 50 M918V carriers, 8 were index cases, 4 were relatives who had already performed total thyroidectomy at the time of RET screening and 38 were relatives who came to RET screening without a history of previous thyroidectomy. From the 38 relatives of this latter group, we have proposed surgical treatment in 8 (F1.1, F1.2, F1.3, F1.4, F1.5, F1.10, F4.1 and F6.1) because we have noticed elevated serum calcitonin and suspicious thyroid nodules or cervical lymph nodes by cervical ultrasound, some of them associated to suspicious or positive results on cytology after FNAB (Table 2). After surgery, we have observed MTC or C-cell hyperplasia (CCH) in all 20 M918V operated carriers (Table 2).

The clinical presentation of MTC in the index cases varied considerably, particularly for the age at diagnosis and the TNM (tumor, node and metastasis) staging (Table 2). For the index cases, the youngest patient was diagnosed with MTC at 24 years of age (F6); however, at age 16, he noticed a nodule on the left side of his neck; the lesion was investigated 8 years later because the nodule persistently increased in volume. He presented the most advanced postoperative TNM stage of this cohort. The oldest M918V index case was diagnosed at 59 years of age (T2mN1bM0), and the follow-up did not reveal evidence of biochemical or structural disease (F5). Additionally, one of the M918V index cases (F8) was diagnosed at age 41 years with a 1-cm MTC confined to the thyroid gland. To date, she has no sign of metastatic lymph nodes, unlike the other index cases (7/8), which had lymph node
Table 1  Clinical and biochemical features of M918V mutation carriers.

<table>
<thead>
<tr>
<th>Features at the first clinical visit after RET screening</th>
<th>All M918V carriers (n=50)</th>
<th>Index cases (n=8)</th>
<th>Relatives (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>41 (7–87)</td>
<td>54.5 (24–59)</td>
<td>Already TT at RET screening (n=4)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>42.6 (±17.3)</td>
<td>48.2 (±12.2)</td>
<td>TT after RET screening (n=8)</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
<td>No TT after RET screening (n=30)</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>6</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcitonin level (pg/mL)</td>
<td>11.7 (1–4640)</td>
<td>2866 (1092–4640)</td>
<td>121.5 (1.3–2695)</td>
</tr>
<tr>
<td>Mean±s.d.</td>
<td>281 (±913.2)</td>
<td>NA</td>
<td>447.5 (±916.3)</td>
</tr>
<tr>
<td></td>
<td>n=33</td>
<td>NA</td>
<td>9.7 (±8.8)</td>
</tr>
<tr>
<td></td>
<td>n=2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA (ng/mL)</td>
<td>1.4 (0.2–105)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Mean±s.d.</td>
<td>6.2 (±19.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTH level (mg/mL)</td>
<td>44.6 (24.3–76.3)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Mean±s.d.</td>
<td>46.5 (±14.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total calcium (mg/dL)</td>
<td>9.5 (8.2–10)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Mean±s.d.</td>
<td>9.4 (±0.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid nodule on the US</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>23</td>
<td></td>
</tr>
</tbody>
</table>

CT, calcitonin; CEA, carcinoembryonic antigen; n, number of patients; PTH, parathyroid hormone; s.d., standard deviation; TT, total thyroidectomy; US, ultrasound.
Reference ranges: Basal plasma calcitonin, males: <18.4 pg/mL, females: <7.8 pg/mL; CEA, smokers: <5.0 ng/mL, non-smokers <3.0 ng/mL; PTH: 15–65 ng/mL; Total calcium, adults: 8.8–10.6 mg/dL, children: 8.5–11.0 mg/dL.
*ANOVA test, Kruskal–Wallis, Dunn test among index cases and subgroups of relatives; ^Chi-square test between thyroidectomized and non-thyroidectomized relatives after RET screening; †Mann–Whitney test between thyroidectomized and non-thyroidectomized relatives after RET screening.
Table 2 Clinical and laboratory findings of M918V RET index cases and relatives with confirmation of MTC/CCH by histopathology.

<table>
<thead>
<tr>
<th>Index patients</th>
<th>Affected relatives</th>
<th>Age at diagnosis (years/gender)</th>
<th>Initial symptoms</th>
<th>Total thyroidectomy at RET screening</th>
<th>Time since initial symptoms (months)</th>
<th>FNAB cytology (Bethesda)</th>
<th>Preoperative sCt (pg/mL)</th>
<th>Surgery extension</th>
<th>Clinical TNM staging</th>
<th>Time of follow-up (months)</th>
<th>Current sCt (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td></td>
<td>54/F Thyroid nodule</td>
<td>Yes</td>
<td>2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>TT + central and right lateral</td>
<td>T3m N0 M0</td>
<td>73</td>
<td>4.3</td>
</tr>
<tr>
<td>F1.1</td>
<td></td>
<td>34/F –</td>
<td>No</td>
<td>II</td>
<td>20</td>
<td>2695</td>
<td>TT + central ND</td>
<td>TT + central ND</td>
<td>T1am N0 M0</td>
<td>50</td>
<td>&lt;2.0</td>
</tr>
<tr>
<td>F1.2</td>
<td></td>
<td>31/M –</td>
<td>No</td>
<td>V (PTC)</td>
<td>116</td>
<td>TT + central right lateral ND</td>
<td>TT + central right lateral ND</td>
<td>T1am N1b M0</td>
<td>50</td>
<td>132</td>
<td></td>
</tr>
<tr>
<td>F1.3</td>
<td></td>
<td>30/M –</td>
<td>No</td>
<td>VI (MTC)</td>
<td>148</td>
<td>TT + central ND</td>
<td>TT + central ND</td>
<td>T1am N0 M0</td>
<td>50</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>F1.4</td>
<td></td>
<td>28/F –</td>
<td>No</td>
<td>III</td>
<td>11.7</td>
<td>TT</td>
<td>TT + central ND</td>
<td>T1am N1a M0</td>
<td>50</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>F1.5</td>
<td></td>
<td>42/F –</td>
<td>No</td>
<td>IV</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>TT + central left lateral ND</td>
<td>T3m N1b M0</td>
<td>50</td>
<td>&lt;2.0</td>
</tr>
<tr>
<td>F1.6</td>
<td></td>
<td>51/F Thyroid nodule</td>
<td>Yes</td>
<td>24</td>
<td>II</td>
<td>NA</td>
<td>NA</td>
<td>TT + central left lateral ND</td>
<td>67</td>
<td>8.2</td>
<td></td>
</tr>
<tr>
<td>F1.7</td>
<td></td>
<td>50/F Thyroid nodule</td>
<td>Yes</td>
<td>17</td>
<td>II</td>
<td>NA</td>
<td>NA</td>
<td>TT</td>
<td>T3m N0 M0</td>
<td>108</td>
<td>50.3</td>
</tr>
<tr>
<td>F1.8</td>
<td></td>
<td>52/M –</td>
<td>Yes</td>
<td>IV</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>TT and central ND</td>
<td>T3m N1a M0</td>
<td>32</td>
<td>219</td>
</tr>
<tr>
<td>F1.9</td>
<td></td>
<td>54/F –</td>
<td>Yes</td>
<td>VI (PTC)</td>
<td>81.5</td>
<td>NA</td>
<td>NA</td>
<td>TT</td>
<td>CCH only</td>
<td>36</td>
<td>&lt;2.0</td>
</tr>
<tr>
<td>F1.10</td>
<td></td>
<td>45/F –</td>
<td>No</td>
<td>III</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>TT + central right lateral ND</td>
<td>T2m N1b M0</td>
<td>88</td>
<td>140</td>
</tr>
<tr>
<td>F2</td>
<td></td>
<td>58/F –</td>
<td>Yes</td>
<td>– V</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>TT + central right lateral ND</td>
<td>T1b N1a M0</td>
<td>73</td>
<td>6.2</td>
</tr>
<tr>
<td>F3</td>
<td></td>
<td>55/F Disturb of swallowing</td>
<td>Yes</td>
<td>2</td>
<td>IV</td>
<td>NA</td>
<td>NA</td>
<td>TT + central/right lateral ND</td>
<td>T3m N1b M1</td>
<td>97</td>
<td>506</td>
</tr>
<tr>
<td>F4</td>
<td></td>
<td>40/F Hoarseness and cervical nodules</td>
<td>Yes</td>
<td>3</td>
<td>VI (MTC)</td>
<td>1092</td>
<td>TT + central/bilateral ND</td>
<td>T3m N1b M1</td>
<td>97</td>
<td>506</td>
<td></td>
</tr>
<tr>
<td>F4.1</td>
<td></td>
<td>68/F –</td>
<td>No</td>
<td>– VI (MTC)</td>
<td>286</td>
<td>TT + central/level VII ND</td>
<td>TT + central/level VII ND</td>
<td>T1bm N1b M0</td>
<td>68</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>F5</td>
<td></td>
<td>59/F Thyroid nodule</td>
<td>Yes</td>
<td>2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>TT + central/ bilateral ND</td>
<td>T2m N1b M0</td>
<td>157</td>
<td>2</td>
</tr>
<tr>
<td>F6</td>
<td></td>
<td>24/M Lateral cervical mass growth</td>
<td>Yes</td>
<td>96</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>TT + central/ bilateral ND</td>
<td>T4am N1b M1</td>
<td>124</td>
<td>1698</td>
</tr>
<tr>
<td>F6.1</td>
<td></td>
<td>59/M –</td>
<td>No</td>
<td>– VI (MTC)</td>
<td>323</td>
<td>TT + central ND</td>
<td>TT + central ND</td>
<td>T1bm N0 M0</td>
<td>45</td>
<td>6.2</td>
<td></td>
</tr>
<tr>
<td>F7</td>
<td></td>
<td>55/M Hoarseness</td>
<td>Yes</td>
<td>60</td>
<td>V</td>
<td>4640</td>
<td>TT + central ND</td>
<td>TT + central ND</td>
<td>T3m N1b M0</td>
<td>54</td>
<td>371</td>
</tr>
<tr>
<td>F8</td>
<td></td>
<td>41/F –</td>
<td>Yes</td>
<td>– IV</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>TT</td>
<td>T1 N0 M0</td>
<td>240</td>
<td>7.5</td>
</tr>
</tbody>
</table>

CCH, C-cell hyperplasia; FNAB, fine needle aspiration biopsy; MTC, medullary thyroid carcinoma; NA, not available; ND, node dissection; PTC, papillary thyroid carcinoma; sCt, serum calcitonin; TNM, tumor, nodal, metastasis (staging according to the American Joint Committee on Cancer-AJCC).

* F1.8 had also a 0.6 cm PTC; ** F1.9 had been previously submitted to total thyroidectomy because of a FNAB cytology positive for PTC. Histopathology review and immunohistochemistry confirmed the PTC (pT3N0Mx) and besides no foci of MTC were found, CCH was identified; † F1.10’s thyroid nodule was in fact a pT1N0Mx PTC. Although no foci of MTC were found, CCH was identified; ‡ this patient presented areas of CCH associated to a focus of MTC; ¤ presumable metastases in patients presenting sCt >500 mg/dL. The imaging abnormalities found in these patients were not biopsied.
involvement at the time of the initial diagnosis. Two patients (F4 and F6), besides lymph node involvement, also presented persistently very elevated calcitonin levels and distant lesions on imaging methods. The F4 index patient presented a 1-cm highly vascularized hepatic nodule seen by abdominal magnetic resonance imaging (MRI), and the last serum calcitonin on the follow-up is 506 pg/mL. Patient F6 has been diagnosed with cervical and thoracic vertebrae lesions suggestive of metastases 3 years after the thyroidectomy by MRI, and the last serum calcitonin on the follow-up is 1698 pg/mL. No increase in the size of those presumable metastatic lesions of both patients was noted during the follow-up. The remaining index patients presented at their last clinical assessment the following status: one had elevated calcitonin levels (140 pg/mL) and cervical lateral lymph nodes (F2); one had elevated calcitonin levels (371 pg/mL) with no structural evidence of disease (F7); 3 had persisted low calcitonin levels (<10 pg/mL) (F1, F3 and F8) and one had undetectable calcitonin (F5) (Table 2). MTC was present in all surgical specimens and in 7/8 patients presenting multifocal tumor. It is noteworthy that some cases were presumably cured, despite relatively late thyroid surgery (F1, F3, F5 and F8).

To date, 12 relatives carrying the M918V mutation have undergone total thyroidectomy, with confirmation of MTC and/or CCH in the histopathology. As mentioned, 4 of these patients had been already submitted to thyroidectomy when they came up to perform RET screening; 3 of them (patients F1.6, F1.7 and F1.8, Table 2) were already aware of MTC diagnosis after RET screening, and one of them (patient F1.9, Table 2) had been submitted to thyroidectomy because of a thyroid nodule positive for papillary thyroid carcinoma (PTC). Histopathological review of F1.9 patient confirmed the PTC besides C-cell hyperplasia. In addition, patients F1.8 and F1.10 also demonstrated small PTCs on surgical specimens (Table 2).

In 7/12 relatives carrying the M918V mutation with MTC/CCH, the disease was restricted to the thyroid gland, and the remainder presented metastatic lymph nodes at diagnosis. Seven of 12 relatives achieved undetectable serum calcitonin in the postoperative evaluation.
The clinical and laboratory findings, as well as the surgical extent of all patients with confirmed MTC/CCH are summarized in Table 2.

For the other 30 M918V carriers, we have decided, after discussions with the medical team and the patients, that a careful follow-up would be a better recommendation than prophylactic surgery because they present normal calcitonin and CEA levels, and no suspicious nodules/lymph nodes on cervical ultrasound. We did not observe statistically significant difference of gender and age between both groups of patients (indicated for surgical treatment, n=8 vs clinical follow-up, n=30). However, the group who performed surgical treatment after RET screening had higher levels of serum calcitonin and a higher frequency of thyroid nodules on the ultrasound (Table 1).

Until the last follow-up visit (up to 5 years of observation), no mutation carrier had presented clinical manifestations or laboratory tests indicating HPTP or PHEO, neither cutaneous lichen amyloidosis nor Hirschsprung’s disease. Importantly, clinical assessment of all MTC patients and mutation carriers did not reveal any typical features of MEN 2B, such as musculoskeletal abnormalities; neuromas in the lips, the tongue or the conjunctiva; or ganglioneuromatosis of the intestine.

None of the 40 control individuals presented with the M918V RET mutation.

Tracking the RET M918V founder effect and age of mutation

Due to the observation that the highest concentration of patients with the M918V RET mutation was in the region that comprises the Jaguaribe River valley and the Apodi plateau (Fig. 2) in the northeast area of the State of Ceará and because the F1 and F6 live in nearby cities (<25 miles) of this region, we investigated the presence of a founder effect.

The ethnographic investigation delved into the historical archives of the region with the highest concentration of M918V-affected patients, studying the family ancestor data in the churches and oral life history narratives. After performing a wide pedigree, we observed that some of the M918V MTC patients from this region who were unaware of MTC in other family members belonged to the same family (F1.6, F1.7 and F1.8) (Fig. 3). In 1700s, a pioneer immigrated to northeastern Brazil from Braga, Portugal, colonizing this region in the northeast of Ceará. Both historical registries and oral life history narratives suggested that this colonizer migrated along the Jaguaribe River valley, where he established several settlements.

The haplotype analysis of our founder effect investigation confirmed the qualitative ethnographic data collected. All studied loci were in Hardy-Weinberg equilibrium. Seven patients (33.3%) from 4 apparently unrelated families shared a common haplotype (D10S197-RET-D10S196-D10S1652: 168-M918V-98-170; Fig. 4A). However, only 2 wild-type chromosomes in the control group presented this haplotype (P<0.001). In fact, statistically significant differences in allele frequencies between the wild-type and the M918V RET chromosomes were observed for markers located closer to RET, in particular D10S197, D10S196 and D10S537. This finding...
supports our hypothesis that the M918V RET mutation was settled in Ceará state as a founder mutation.

The State of Ceará’s population currently includes 8,904,459 people (Instituto Brasileiro de Geografia e Estatística 2015). Historical and demographic data indicate that the population was 721,686 in 1872 (Instituto Brasileiro de Geografía e Estatística 1872). Assuming 25 years/generation, the estimated growth rate was 0.4411, and assuming 30 years/generation, the estimated growth rate was 0.5294. Figure 4B presents a set of histograms for age estimation. Briefly, we estimated that the founder mutation was settled in Ceará approximately 15 generations ago, which corresponds to 376 years (considering the year/generation 25 years) or 451 years (considering the year/generation 30 years).

The phylogenetic tree (Fig. 4C) revealed that control group shared poor genetic similarity with the patients. Our tree findings revealed that all families coalesce in a common knot, corresponding to a putative most recent common ancestor. Most importantly, our data indicate that different families may be related to each other.

**Discussion**

By studying 8 kindreds affected by the RET M918V mutation, we report for the first time that this mutation co-segregates with familial MTC and is inherited with complete penetrance pattern. The RET 918 codon is classically related to the MEN 2B syndrome and has been extensively studied since the first mutation in this codon was reported (Carlson et al. 1994, Hofstra et al. 1994, Eng et al. 1994, Cirafici et al. 1997, Wells et al. 2015). In contrast to the M918T mutation, which causes MEN 2B syndrome with a more aggressive MTC, we did not detect any MEN 2B features in the M918V carriers and a more favorable outcome compared with classical highest-risk M918T mutation carriers. In fact, the clinical presentation was quite heterogeneous, particularly for the age at diagnosis, the TNM staging and the follow-up after thyroidecotomy (Table 2). The advanced TNM stage in 2 index cases (F6 and F7, Table 2) was possibly related to the long interval from the manifestation of the initial symptoms to surgical treatment; their follow-up was also remarkable for the highest levels of postoperative serum calcitonin and CEA, suggesting the persistence of disease.

For the relatives whose diagnosis of MTC was performed after the genetic screening, we observed that the mothers (F4.1 and F6.1) of 2 probands had less advanced disease than their children. This finding reinforces the importance of RET mutation screening to diagnose the tumor before the onset of symptoms. Interestingly, we observed that patient F1.8 was diagnosed at 52 years of age with a tumor (T3mN1aM0) and a micro PTC, whereas his sister (F1.9), who was also submitted to total thyroidecotomy due to PTC, presented only CCH. Additionally, an 87-year-old male with a normal calcitonin level and thyroid ultrasound without any nodules recently died from an unrelated condition, whereas his grandson was diagnosed with a multifocal MTC and lateral lymph node metastases at 31 years of age (F1.2) (Table 2). We believe that genetics and environmental factors may contribute to the wide clinical heterogeneity of our patients (Rigotto et al. 2012).

It is well known that, even in large kindreds, the pattern of disease presentation may not become evident until the evaluation of several family members, and even then, it may vary compared with reports of other...
families with the same RET mutation (Wells et al. 2013). Taking into consideration that we have observed only 20 patients with M918V MTC/CCH to date, cervical lymph node metastases were found in 12/20 patients, including 3 patients younger than 35 years (F1.2, F1.4, and F6), and probable distant metastases were noted in 2/20, suggesting a more aggressive behavior of M918V MTC. Patients F4 and F6 presented structural lesions in liver and spinal vertebrae, respectively, which could correspond to distant metastases as they are associated to persistent high levels of calcitonin (above 500 pg/mL). However, false-positive results cannot be totally excluded, as these abnormalities were not biopsied.

On the other hand, we observed a relatively favorable presentation among the majority of carriers. Therefore, we believe that assessment and follow-up of a greater number of patients carrying M918V is necessary to get a better understanding about the behavior of MTC related to this novel mutation. In general, a substantial number of patients with distant metastases of MTC may have indolent disease and quiescent or slow-growing lesions over years of routine observation (Cabanillas et al. 2014).

So far, 20 out of 50 M918V carriers underwent total thyroidectomy and all of them presented MTC/CCH in surgical specimens (Table 2). It is possible that 30 M918V remaining carriers, who were not submitted to surgical treatment, may present microscopic MTC/CCH whose size did not influence basal calcitonin levels or the formation of a thyroid nodule on US imaging yet. Therefore, we faced an issue that was discussed among the medical team as to how we would deal with M918V carriers who did not present any test suggesting the presence of MTC/CCH. Presently, there is no recommendation in guidelines about prophylactic thyroidectomy for M918V, so we have decided by a cautious follow-up using basal calcitonin and neck US performed at every 6-month interval.

In fact, when we initially found the first patients with M918V, we were not sure that M918V was a mutation causing disease as up to the present time, the only mutation described in codon 918 was the M918T, classically associated to the MEN 2B phenotype. For those reasons, we opted to perform RET extended analysis in all M918V who had histopathological confirmation of MTC or CCH. Also, M918V had not been found in 40 thyroid-healthy controls from the same country state.

Moreover, we observed that 2 patients carrying M918V mutation had CCH and PTC (F1.9 and F1.10, Table 2) and 1 patient (F1.8, Table 2) had MTC and PTC. The association of PTC and MTC occasionally occurs, which comes in a variable rate (Biscolla et al. 2004, Machens & Dralle 2012), depending on the environmental conditions or differences in the study populations (Wells et al. 2015).

We further investigated the ethnographic and quantitative aspects of the dispersion of the M918V RET mutation. All of our data support the hypothesis that a founder effect is responsible for the dispersion of the M918V RET mutation along the Jaguaribe River throughout the State of Ceará, consistent with the higher prevalence of MTC around the northeast of the state. Therefore, our findings substantiate both anecdotal and community health-based evidence collected from the participants during the ethnographic fieldwork. We propose that the Brazilian growth rate followed distinct phases in history and that the constant growth rate portrayed here is a mere mathematical extrapolation. It is also noteworthy that the historical registries of the population in the studied region were not precisely accounted for as we journeyed into the past. However, we encountered consistent information with the aid of the oral life history narratives and the document analysis, which corroborated to our hypothesis that this mutation has accompanied the population of Ceará for approximately 350–400 years and that these 8 supposedly distinct kindreds are one single family that has been dismembered through the years.

Considering the results of biochemical and/or imaging tests used for the investigation of MTC, and the histopathological results for those patients who were submitted to surgical treatment, we observed a low penetration of this neoplasia among M918V carriers (~40% (20/50)). Also, evaluating the median age of the relatives who were M918V carriers according to their status at the RET screening (already thyroidectomized at RET screening with MTC/CCH confirmation by histopathology: 51.5 years; thyroidectomized after RET screening with MTC/CCH confirmation by histopathology: 36.5 years vs non-thyroidectomized after RET screening: 36.5 years, Table 1), we observed a relatively lower progression of MTC in all subgroups of carriers.

The majority of the MTC patients presented a favorable clinical course, even though there are high frequency of lymph node metastases at initial diagnosis and presumable distant metastasis in 2 patients. In conclusion, based on the heterogeneity of clinical presentation of M918V mutation in our case series, we propose that this mutation should be classified as an ATA moderate-risk mutation and that M918V carriers must undergo total thyroidectomy and neck dissection as appropriate, whenever elevated serum calcitonin or suspicious thyroid nodules or cervical lymph nodes are found. For the M918V carriers without biochemical or imaging tests suggestive of MTC, we believe...
that prophylactic thyroidectomy could be postponed beyond 10 years of age (Wells et al. 2013, 2015).

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by research grants from the Sao Paulo State Research Foundation (FAPESP) to R M B M, J R M M, M R D-S (2006/60402-1) and to R M B M (2010/51547-1 and 2014/06570-6) by FAPESP fellowship grants to S C L (2009/50575-4) and to M S A S (2010/51546-S and 2012/1942-1) and by a Fleury Group Research Grant (12518). R M B M and A L M are investigators of the Fleury Group.

Author contribution statement
Drs Dias-da-Silva and Maciel had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Martins, Dias-da-Silva and Maciel contributed to study concept and design. Martins-Costa, Cunha, Lindsey, Camacho, Dotto, Furuzawa, Sousa, Kasamatsu, Kunii, Martins, Machado, Martins, Dias-da-Silva and Maciel contributed to the acquisition, analysis or interpretation of data. Martins-Costa, Martins, Dias-da Silva and Maciel drafted the manuscript. Cunha, Sousa, Martins, Dias-da-Silva, and Maciel critically revised the manuscript for important intellectual content. Cunha and Camacho contributed to statistical analysis. Martins, Dias-da-Silva and Maciel obtained funding. Administrative, technical, or material support was given by Furuzawa, Kasamatsu and Kunii. Study was supervised by Martins, Dias-da-Silva and Maciel.

Acknowledgments
The authors are thankful for the Cooperation for the Improvement of Higher Education Personnel, Brazil-Ministry of Education (CAPES) for the support to our Post-Graduation Program. The authors are thankful to the team of the Laboratory of Molecular and Translational Endocrinology. The authors are also thankful to the surgeons in Ceará who performed the surgeries in our patients: André P Cortez, Marcelo E Holanda, Fernando Porto Carreiro-Filho, J Wilson M de Farias, Sérgio B Lima and Luís A Albano Ferreira. Also, the authors acknowledge all patients and relatives who kindly hosted our regional BRASMEN task force in northeast Ceará.

References
Frank-Raue K & Raue F 2015 Hereditary medullary thyroid cancer genotype-phenotype correlation. Recent Results in Cancer Research 204. 139–156. (doi:10.1007/978-3-213-22524-5_6)


